Also known as: amyloid-β, Aβ
University of Galway researchers identified that targeting GABA signaling, specifically α5-GABA A receptors, can restore neural balance and improve memory in Alzheimer's disease models, offering a potential new therapeutic approach distinct from current excitatory-focused treatments.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
A 16-year study links higher vitamin D levels in middle age to lower tau protein deposits in the brain, while a major COVID-19 trial finds vitamin D doesn't reduce acute severity but may help with long COVID recovery. Separate research shows supplementation improves vitamin D levels and stabilizes immune profiles in athletes and non-athletes.
New research reveals significant advances in blood-based biomarkers for Alzheimer's disease, including a pTau 217 assay showing 93% agreement with amyloid PET imaging and identification of interferon gamma as a diagnostic signal linked to genetic risk. These developments address challenges in early diagnosis and monitoring while requiring substantially less plasma than previous tests.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
New market research reports analyze biotechnology collaboration agreements from 2020-2026, gas chromatography market growth projections, and Western blotting market trends through 2035.
Recent studies demonstrate brain stimulation therapies can accelerate depression treatment to five days and low-dose lithium may slow cognitive decline in seniors with mild cognitive impairment.
New research identifies a key microglial subpopulation regulated by anti-TREM2 antibody therapy in Alzheimer's disease, revealing how the treatment guides microglia toward protective differentiation pathways.
